{"name":"Thinq Pharma-CRO Pte. Ltd.","slug":"thinq-pharma-cro-pte-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Roxane Laboratories Inc., USA","genericName":"Roxane Laboratories Inc., USA","slug":"roxane-laboratories-inc-usa","indication":"Attention deficit hyperactivity disorder","status":"phase_3"},{"name":"Unique Pharmaceutical Laboratories, India","genericName":"Unique Pharmaceutical Laboratories, India","slug":"unique-pharmaceutical-laboratories-india","indication":"Phase 3 clinical trials for an unspecified indication","status":"phase_3"}]}],"pipeline":[{"name":"Roxane Laboratories Inc., USA","genericName":"Roxane Laboratories Inc., USA","slug":"roxane-laboratories-inc-usa","phase":"phase_3","mechanism":"Roxane Laboratories Inc., USA's drug is a central nervous system stimulant.","indications":["Attention deficit hyperactivity disorder"],"catalyst":""},{"name":"Unique Pharmaceutical Laboratories, India","genericName":"Unique Pharmaceutical Laboratories, India","slug":"unique-pharmaceutical-laboratories-india","phase":"phase_3","mechanism":"Unique Pharmaceutical Laboratories' drug is a small molecule in phase 3 clinical trials.","indications":["Phase 3 clinical trials for an unspecified indication"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}